Antibody-based drug helps 'bridge' leukemia patients to curative treatment

(University of Texas M. D. Anderson Cancer Center) In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.